Total Payments
$191,262
2024 Payments
$2,571
Companies
79
Transactions
1,476
Medicare Patients
18,725
Medicare Billing
$3.8M
Payment Breakdown by Category
Other$140,677 (73.6%)
Consulting$25,152 (13.2%)
Food & Beverage$22,293 (11.7%)
Travel$2,394 (1.3%)
Education$746.70 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $137,241 | 116 | 71.8% |
| Consulting Fee | $25,152 | 32 | 13.2% |
| Food and Beverage | $22,293 | 1,252 | 11.7% |
| Travel and Lodging | $2,394 | 35 | 1.3% |
| Honoraria | $1,675 | 5 | 0.9% |
| Long term medical supply or device loan | $1,196 | 12 | 0.6% |
| Education | $746.70 | 23 | 0.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $565.00 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $49,258 | 139 | $0 (2023) |
| Celgene Corporation | $22,996 | 84 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $20,381 | 38 | $0 (2023) |
| Seattle Genetics, Inc. | $12,840 | 16 | $0 (2019) |
| Genentech USA, Inc. | $9,580 | 100 | $0 (2023) |
| Astellas Pharma US Inc | $9,357 | 33 | $0 (2023) |
| Amgen Inc. | $9,117 | 76 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $8,746 | 59 | $0 (2023) |
| Millennium Pharmaceuticals, Inc. | $5,723 | 10 | $0 (2017) |
| Mirati Therapeutics, Inc. | $5,312 | 20 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,571 | 13 | BeiGene USA, Inc. ($1,375) |
| 2023 | $12,080 | 206 | Mirati Therapeutics, Inc. ($5,312) |
| 2022 | $12,627 | 164 | Incyte Corporation ($4,082) |
| 2021 | $11,802 | 122 | AstraZeneca Pharmaceuticals LP ($6,471) |
| 2020 | $16,044 | 158 | AstraZeneca Pharmaceuticals LP ($5,906) |
| 2019 | $51,033 | 291 | Genentech USA, Inc. ($8,847) |
| 2018 | $50,119 | 270 | AstraZeneca Pharmaceuticals LP ($18,937) |
| 2017 | $34,985 | 252 | Celgene Corporation ($13,295) |
All Payment Transactions
1,476 individual payment records from CMS Open Payments — Page 1 of 60
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 11/11/2024 | BeiGene USA, Inc. | TEVIMBRA (Drug) | Consulting Fee | Cash or cash equivalent | $1,375.00 | General |
| Category: Oncology | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 08/23/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 07/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 06/13/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 05/16/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 04/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 03/15/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 02/16/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 01/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Long term medical supply or device loan | In-kind items and services | $99.70 | General |
| Category: Oncology | ||||||
| 12/13/2023 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $27.27 | General |
| Category: Oncology | ||||||
| 12/13/2023 | Janssen Biotech, Inc. | TALVEY (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Oncology | ||||||
| 12/12/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,387.50 | General |
| Category: Oncology | ||||||
| 12/12/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $25.93 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2023 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: ONCOLOGY | ||||||
| 12/07/2023 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $25.67 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2023 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Rare Disease | ||||||
| 12/06/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $9.27 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2023 | Puma Biotechnology, Inc. | — | Food and Beverage | In-kind items and services | $17.65 | General |
| 11/29/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $7.42 | General |
| Category: Hematology | ||||||
| 11/28/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: Oncology | ||||||
| 11/28/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 55 | 3,271 | 45,780 | $1.4M | $437,950 |
| 2022 | 60 | 3,923 | 91,137 | $2.5M | $825,957 |
| 2021 | 62 | 4,341 | 104,839 | $2.8M | $818,423 |
| 2020 | 76 | 7,190 | 297,504 | $5.3M | $1.7M |
Total Patients
18,725
Total Services
539,260
Medicare Billing
$3.8M
Procedure Codes
253
All Medicare Procedures & Services
253 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 19 | 3,660 | $109,800 | $66,855 | 60.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 306 | 908 | $190,680 | $63,122 | 33.1% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 33 | 53 | $302,100 | $62,294 | 20.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 137 | 350 | $105,000 | $34,342 | 32.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 56 | 278 | $91,740 | $29,040 | 31.7% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 33 | 57 | $38,817 | $22,944 | 59.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 16 | 117 | $52,500 | $15,758 | 30.0% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 21 | 2,100 | $50,400 | $12,339 | 24.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 387 | 1,635 | $49,050 | $12,337 | 25.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 306 | 1,026 | $30,780 | $10,578 | 34.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 337 | 1,164 | $17,460 | $9,770 | 56.0% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 24 | 22,440 | $48,960 | $8,981 | 18.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 26 | 136 | $17,000 | $7,809 | 45.9% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 12 | 1,220 | $24,400 | $7,373 | 30.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 51 | 124 | $18,600 | $6,408 | 34.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 70 | 263 | $22,355 | $6,181 | 27.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 68 | 90 | $14,850 | $5,964 | 40.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 30 | 30 | $15,600 | $5,044 | 32.3% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2023 | 15 | 23 | $33,350 | $4,856 | 14.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 19 | 74 | $12,210 | $3,926 | 32.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 26 | $11,960 | $3,630 | 30.4% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 59 | 173 | $9,515 | $3,214 | 33.8% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 122 | 238 | $9,520 | $3,166 | 33.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 64 | 241 | $13,255 | $3,052 | 23.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 19 | $7,980 | $2,826 | 35.4% |
About Dr. Michael Wertheim, MD
Dr. Michael Wertheim, MD is a Hematology & Oncology healthcare provider based in Fort Myers, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982643474.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Wertheim, MD has received a total of $191,262 in payments from pharmaceutical and medical device companies, with $2,571 received in 2024. These payments were reported across 1,476 transactions from 79 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($137,241).
As a Medicare-enrolled provider, Wertheim has provided services to 18,725 Medicare beneficiaries, totaling 539,260 services with total Medicare billing of $3.8M. Data is available for 4 years (2020–2023), covering 253 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Fort Myers, FL
- Active Since 06/06/2006
- Last Updated 10/30/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1982643474
Products in Payments
- IMFINZI (Drug) $26,741
- NINLARO (Drug) $25,717
- ADCETRIS (Biological) $15,893
- TAGRISSO (Drug) $15,112
- Revlimid (Drug) $12,737
- Abraxane (Drug) $8,730
- XTANDI (Drug) $8,607
- Nplate (Biological) $7,346
- IMFINZI (Biological) $6,654
- TECENTRIQ (Biological) $6,627
- KRAZATI (Drug) $5,312
- OPDIVO (Biological) $4,624
- Braftovi (Drug) $4,451
- Xtandi (Drug) $3,069
- ERBITUX (Drug) $2,991
- ROZLYTREK (Biological) $2,125
- KISQALI (Drug) $1,434
- Venclexta (Drug) $1,386
- TEVIMBRA (Drug) $1,375
- KEYTRUDA (Biological) $1,285
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fort Myers
Dr. Anamika Katoch, M.d, M.D
Hematology & Oncology — Payments: $223,955
Hematology & Oncology $223,955
Dr. Jorge Perez De Armas, Md, MD
Hematology & Oncology — Payments: $3,370
Hematology & Oncology $3,370
Divis Khaira, M.d, M.D
Hematology & Oncology — Payments: $567.18
Hematology & Oncology $567.18
Dr. Brian Kim, M.d, M.D
Hematology & Oncology — Payments: $503.79
Hematology & Oncology $503.79
Ricky Chen, M.d, M.D
Hematology & Oncology — Payments: $225.62
Hematology & Oncology $225.62
Dr. Scott Dunbar, M.d, M.D
Hematology & Oncology — Payments: $48.82
Hematology & Oncology $48.82